Geron (GERN) Finished Goods (2024)

Geron's (GERN) quarterly Finished Goods came in at $3.7 million in Q4 2024, up 328.23% quarter-over-quarter from $868000.0 in Q3 2024.

Geron (GERN) Finished Goods (2024) Analysis & Trends

Geron has disclosed Finished Goods across 1 years of filings, most recently posting $3.7 million for Q4 2024.

Finished Goods for Q4 2024 came in at $3.7 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was $3.7 million (changed N/A YoY), and the FY2024 annual result was $3.7 million, changed N/A from the prior year.
Finished Goods came in at $3.7 million for Q4 2024 at Geron, up from $868000.0 in the prior quarter.
In the past five years, Finished Goods ranged from a high of $3.7 million in Q4 2024 to a low of $774000.0 in Q2 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn
9	Abivax	91.71 Bn	91.71 Bn	-
10	Geron	729,618.77	729,618.77	-

Download Data